Tufts CSDD research on non-rare disease trials put the average screen failure rate at 36.3%, up from 34.7% in 2012. In rare disease trials, 81% of patients screened were not eligible (Applied Clinical Trials). An earlier Tufts CSDD study of 151 global trials found that, on average, 928 patients were screened, 622 enrolled and 516 completed, with one in six enrolled patients dropping out (Applied Clinical Trials).
Most studies track one recruitment number: patients randomised against target. By the time that number is behind, the cause happened weeks earlier, somewhere between the first referral and the screening visit. The seven metrics below show where patients are being lost, so the team can act before enrollment falls behind.
|
Funnel stage |
What is lost here |
Metric that shows it |
|---|---|---|
|
Outreach |
Channels that bring interest but not eligible patients |
Yield by referral source |
|
Pre-screening |
Ineligible people reaching the site |
Pre-screen pass rate |
|
First contact |
Interested people who go cold |
Time from referral to first contact |
|
Screening |
Patients failing specific criteria |
Screen failure rate by criterion |
|
Consent to randomisation |
Eligible patients who don't start |
Consent-to-randomisation rate |
|
Treatment and follow-up |
Patients who leave the study |
Dropout rate |
|
Whole funnel |
Spend that doesn't produce patients |
Cost per randomised patient by channel |
Count how many randomised patients each source produces: site databases, physician referrals, advertising, social media, patient communities. Channels that generate many enquiries and few randomisations take up coordinator time without adding patients.
The share of pre-screened people who go on to a screening visit. A low rate means pre-screening questions are missing a criterion that later rules people out. A very high rate followed by high screen failure means the same thing.
Interest fades quickly. Track how long it takes for a referral to receive a call or message from the site, and set a target. This metric is entirely in the study team's control.
An overall screen failure rate tells you there is a problem. Screen failures broken down by the criterion that caused them tell you which one. If one criterion accounts for most failures, either pre-screening should check it, or the protocol team should review it.
Patients who consent but are never randomised point to problems between screening and the first treatment visit, such as long washout periods, scheduling or travel. These are often fixable with logistics support.
With one in six enrolled patients leaving before completion in the Tufts data, retention is part of recruitment. Track dropout by site, visit and reason, and look at visit burden, travel and reimbursement for the visits where people leave.
Spend divided by randomised patients, per channel, shows which campaigns are worth continuing. Cost per enquiry flatters channels that bring volume but not eligibility.
Cloudbyz Patient Recruitment is built natively on Salesforce for sponsors, CROs, site networks and sites. According to Cloudbyz product materials, it covers study websites, social media and email or SMS campaigns, a volunteer portal, pre-screening by web, SMS and chatbot, eligibility and study matching, phone screening with call tracking, appointment booking, travel and hospitality management, recruitment budget management, eConsent and eCheck-in, cohort segmentation, and recruitment metrics and dashboards. Because it shares a platform with Cloudbyz CTMS and EDC, a volunteer's progress from referral to randomisation can be tracked in one place. Which metrics are available depends on how campaigns and screening workflows are configured.
Book a demo or visit cloudbyz.com.